98%
921
2 minutes
20
Nano-QSAR model allows for prediction of the toxicity of materials that have not been experimentally tested before by linking the nano-related structural properties with the biological responses induced by nanomaterials. Prediction of adverse effects caused by substances without having to perform time- and cost-consuming experiments makes QSAR models promising tools for supporting risk assessment. However, very often, newly developed nano-QSAR models are not used in practice due to the complexity of their algorithms, the necessity to have experience in chemoinformatics, and their poor accessibility. In this perspective, the aim of this paper is to encourage developers of the QSAR models to take the effort to prepare user-friendly applications based on predictive models. This would make the developed models accessible to a wider community, and, in effect, promote their further application by regulators and decision-makers. Here, we describe a web-based application that enables to predict the transcriptomic pathway-level response perturbated in the lungs of mice exposed to multiwalled carbon nanotubes. The developed application is freely available at http://aop173-event1.nanoqsar-aop.com/apps/aop_app. It requires only two types of input information related to analyzed nanotubes (their length and diameter) to assess the doses that initiate the inflammation process that may lead to lung fibrosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/17435390.2022.2064250 | DOI Listing |
Pediatr Pulmonol
September 2025
Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.
Background: The approval of cystic fibrosis transmembrane conductance regulator modulators elexacaftor/tezacaftor/ivacaftor (ETI), has significantly improved pulmonary function for people with cystic fibrosis (pwCF). However, the effects on CF-related bone disease and body composition remain unclear.
Methods: This retrospective real-world study examined adults with CF who received ETI treatment.
Allergol Immunopathol (Madr)
September 2025
Department of Emergency Medicine, Tuzla State Hospital, İstanbul, Turkey.
Desensitization is an immunological process that creates temporary tolerance to a drug, which disappears once treatment is discontinued. Ciprofloxacin is a commonly used antibiotic, particularly for chronic lung diseases, yet there are very few desensitization protocols for it. Two ciprofloxacin desensitization schemes were developed a long time ago.
View Article and Find Full Text PDFClin Respir J
September 2025
Department of Thoracic Surgery, Taizhou Hospital, Taizhou, Zhejiang, China.
Background: Persistent inflammation is a crucial characteristic of idiopathic pulmonary fibrosis (IPF). Gut microbiota (GM) contribute to the occurrence and development of several pulmonary diseases through the "gut-lung axis." The genetic role of GM in IPF and the mediating effect of circulating inflammatory proteins.
View Article and Find Full Text PDFIntroduction: Interstitial pneumonia with autoimmune features (IPAF) describes a rare condition characterized by interstitial lung disease (ILD) with autoimmune manifestations in the absence of defined autoimmune rheumatic diseases (AIRD). Although the classification was established in 2015, prospective data on disease progression remain limited.
Objectives: To identify predictors of ILD progression in IPAF patients using three criteria: 1) progressive pulmonary fibrosis (PPF), 2) INBUILD criteria, 3) absolute FVC decline ≥10%.
Pulm Circ
July 2025
Division of Pulmonary, Critical Care, and Sleep Medicine Tufts Medical Center Boston Massachusetts USA.
Pulmonary arterial hypertension (PAH) is characterized by vasoconstriction, proliferation, fibrosis, and microthrombosis of the pulmonary vasculature, which causes elevated pulmonary arterial pressure and vascular resistance leading to right ventricular failure and death. Previous treatments targeted three known pathways involved in the development of PAH: endothelin, nitric oxide, and prostacyclin. Dysfunctional signaling of the transforming growth factor-beta (TGF-β) family, via bone morphogenetic protein (BMP) receptor 2 and activin signaling, has also been implicated in PAH leading to the development of a new class of therapies.
View Article and Find Full Text PDF